Abstract
Objective
To test the hypotheses that (1) CYP2D6 genotype is associated with pharmacokinetics of ophthalmic timolol and (2) variation in genotypes of ADRB1 (β1-adrenoceptor) and GNAS1 (α-subunit of G-protein) modulate heart rate (HR), and systolic (SAP) and diastolic (DAP) arterial pressure responses to timolol.
Methods
Nineteen glaucoma patients and eighteen healthy volunteers were treated with 0.5% aqueous and 0.1% hydrogel formulations of ophthalmic timolol using a randomised cross-over design. The participants conducted head-up tilt and maximum exercise test at four visits. Plasma concentration of timolol was measured twice for glaucoma patients and ten times for healthy volunteers on each visit. Also, the genotypes for CYP2D6, ADRB1 and GNAS1 were determined.
Results
Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (Cmax, values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T1/2, 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng·h/ml) than intermediate [IMs, n=6, mean±SD 1.73±0.59 ng/ml (not significant), 3.30±0.48 h, 11.32±3.72 ng·h/ml], extensive (EMs, n=8, 1.60±0.72 ng/ml, 3.24±1.24 h, 8.52±6.12 ng·h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng·h/ml) metabolisers. The IMs, EMs and UMs did not differ from each other for any of the kinetic variables. Also, the elevation of HR from rest to maximum level tended to differ between PMs and IMs, and between PMs and UMs. The pharmacokinetics and pharmacodynamics between the CYP2D6 groups did not differ with statistical significance when hydrogel timolol was used. Upon head-up tilt, the Ser49 homozygotes (n=26) had higher SAP (P=0.03) and DAP (P<0.01) than the Gly carriers (n=11). The change in DAP from rest to maximum during exercise was lower (P<0.01) in subjects with CC alleles of GNAS1 (n=13) than those with at least one T allele (n=24).
Conclusion
The CYP2D6 poor metabolisers may be more prone to systemic adverse events with aqueous timolol than extensive metabolisers. Since CYP2D6 genotyping is not routine clinical practice, using 0.1% timolol hydrogel instead of 0.5% aqueous preparation will increase patient safety.
Similar content being viewed by others
References
al-Sereiti MR, Edeki T, Lledo P, Turner P (1990) The effects of timolol on intraocular pressure and exercise heart rate in poor and extensive debrisoquine metabolizers. Int J Clin Pharmacol Res 10:339–345
Brodde OE (1991) Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43:203–242
Diggory P, Cassels-Brown A, Vail A, Hillman JS (1998) Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol 82:146–149
Edeki TI, He H, Wood AJ (1995) Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 274:1611–1613
Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491
Huupponen R, Kaila T, Lahdes K, Salminen L, Iisalo E (1991) Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine. J Ocul Pharmacol 7:183–187
Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, Lloyd DD, Brown MJ (1999) Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 34:8–14
Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF (2003) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74:44–52
Kaila T, Karhuvaara S, Huupponen R, Iisalo E (1993) The analysis of plasma kinetics and beta-receptor binding and -blocking activity of timolol following its small intravenous dose. Int J Clin Pharmacol Ther Toxicol 31:351–357
Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, Tzvetkov M, Meineke I, Roots I, Brockmoller J (2004) Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 76:302–312
Koytchev R, Alken RG, Vlahov V, Kirkov V, Kaneva R, Thyroff-Friesinger U, Rehak E (1998) Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 54:469–474
Lennard MS, Lewis RV, Brawn LA, Tucker GT, Ramsay LE, Jackson PR, Woods HF (1989) Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol 27:429–434
Lennard MS, Tucker GT, Woods HF (1986) The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet 11:1–17
Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429–30435
Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF (1985) Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 19:329–333
Liggett SB (2003) Polymorphisms of adrenergic receptors: variations on a theme. Assay Drug Dev Technol 1:317–326
Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14:143–149
Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670–12674
McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW (1985) Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin Pharmacol Ther 38:409–413
Muller B, Zopf K, Bachofer J, Steimer W (2003) Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 49:1624–1631
Newton GE, Azevedo ER, Parker JD (1999) Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study. Circulation 99:2402–2407
Nieminen T, Uusitalo H, Turjanmaa V, Bjarnhall G, Hedenstrom H, Maenpaa J, Ropo A, Heikkila P, Kahonen M (2005) Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 61:369–374
Nino J, Tahvanainen K, Uusitalo H, Turjanmaa V, Hutri-Kähönen N, Kaila T, Ropo A, Kuusela T, Kähönen M (2002) Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Clin Physiol Funct Imaging 22:271–278
O’Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ (2000) The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 99:233–238
Rathz DA, Brown KM, Kramer LA, Liggett SB (2002) Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39:155–160
Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12:465–472
Rouland JF, Morel-Mandrino P, Elena PP, Polzer H, Sunder Raj P (2002) Timolol 0.1% gel (Nyogel 0.1%) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica 216:449–454
Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S, Visvikis S (2004) Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 5:779–802
Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43:381–411
Smith RL (1985) Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance. Eur J Clin Pharmacol 28 (Suppl):77–84
Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, Prasad HC, Byrne DW, Nair UB, Wood AJ, Stein CM (2003) A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 73:366–371
Stewart WC, Stewart JA, Crockett S, Kubilus C, Brown A, Shams N (2002) Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand 80:272–276
Waldock A, Snape J, Graham CM (2000) Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 84:710–713
Van Buskirk EM (1980) Adverse reactions from timolol administration. Ophthalmology 87:447–450
Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536–544
Acknowledgements
Mrs. Pirjo Järventausta and Ms. Nina Peltonen are acknowledged for their skillful technical assistance. The experiments comply with the current Finnish laws.
Author information
Authors and Affiliations
Corresponding author
Additional information
Financial support has been received from the Medical Research Fund of Tampere University Hospital, Emil Aaltonen Foundation and Santen Oy, Tampere, Finland.
Rights and permissions
About this article
Cite this article
Nieminen, T., Uusitalo, H., Mäenpää, J. et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 61, 811–819 (2005). https://doi.org/10.1007/s00228-005-0052-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0052-4